IGFBP7: An oncosuppressor gene in thyroid carcinogenesis

Oncogene

Volumn 29, Issue 26, 2010, Pages 3835-3844

  Vizioli, M G ^a   Sensi, M ^a   Miranda, C ^a   Cleris, L ^a   Formelli, F ^a   Anania, M C ^a   Pierotti, M A ^a   Greco, A ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

IGFBP7; PTC; thyroid tumors

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 7; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE ARREST; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA TRANSFECTION; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR SUPPRESSOR GENE;

CELL ADHESION; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; ONCOGENES; THYROID NEOPLASMS;

EID: 77954243848     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.136     Document Type: Article

References (31)

1. Ahmed S, Yamamoto K, Sato Y, Ogawa T, Herrmann A, Higashi S et al. (2003). Proteolytic processing of IGFBP-related protein-1 (TAF/angiomodulin/ mac25) modulates its biological activity. Biochem Biophys Res Commun 310: 612-618.
2. Akaogi K, Okabe Y, Sato J, Nagashima Y, Yasumitsu H, Sugahara K et al. (1996). Specific accumulation of tumor-derived adhesion factor in tumor blood vessels and in capillary tube-like structures of cultured vascular endothelial cells. Proc Natl Acad Sci USA 93: 8384-8389.
3. Aldred MA, Huang Y, Liyanarachchi S, Pellegata NS, Gimm O, Jhiang S et al. (2004). Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22: 3531-3539.
4. Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, Seth AK. (2005). Essential roles of IGBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer 41: 1515-1527.
5. Chen Y, Pacyna-Gengelbach M, Ye F, Knosel T, Lund P, Deutschmann N et al. (2007). Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J Pathol 211: 431-438.
6. Davies L, Welch HG. (2006). Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295: 2164-2167.
7. Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, Cleris L et al. (2008). Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab Invest 88: 474-481.
8. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D et al. (2005). Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24: 6646-6656.
9. Greco A, Borrello MG, Miranda C, DeglInnocenti D, Pierotti MA. (2009). Molecular pathology of differentiated thyroid cancer. Q J Nucl Med Mol Imaging 53: 440-453.
10. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S et al. (2005). The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102: 19075-19080.
11. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J et al. (2009). Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One 4: e8357.
12. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K et al. (2001). Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 98: 15044-15049.
13. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M et al. (2005). Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65: 1587-1597.
14. Kanemitsu N, Kato MV, Miki T, Komatsu S, Okazaki Y, Hayashizaki Y et al. (2000). Characterization of the promoter of the murine mac25 gene. Biochem Biophys Res Commun 279: 251-257.
15. Latini FR, Hemerly JP, Oler G, Riggins GJ, Cerutti JM. (2008). Re-expression of ABI3-binding protein suppresses thyroid tumor growth by promoting senescence and inhibiting invasion. Endocr Relat Cancer 15: 787-799.
16. Lin J, Lai M, Huang Q, Ma Y, Cui J, Ruan W. (2007). Methylation patterns of IGFBP7 in colon cancer cell lines are associated with levels of gene expression. J Pathol 212: 83-90.
17. Lowe SW, Cepero E, Evan G. (2004). Intrinsic tumour suppression. Nature 432: 307-315.
18. Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F et al. (2008). Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res 68: 6770-6778.
19. Ruan W, Xu E, Xu F, Ma Y, Deng H, Huang Q et al. (2007). IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol Ther 6: 354-359.
20. Ruan WJ, Lin J, Xu EP, Xu FY, Ma Y, Deng H et al. (2006). IGFBP7 plays a potential tumor suppressor role against colorectal carcino-genesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B 7: 929-932.
21. Sato Y, Chen Z, Miyazaki K. (2007). Strong suppression of tumor growth by insulin-like growth factor-binding protein-related protein 1/tumor-derived cell adhesion factor/mac25. Cancer Sci 98: 1055-1063.
22. Schrama D, Kneitz H, Willmes C, Adam C, Houben R, Becker JC. (2010). Lack of correlation between IGFBP7 expression and BRAF mutational status in melanoma. J Invest Dermatol 130: 897.
23. Sprenger CC, Damon SE, Hwa V, Rosenfeld RG, Plymate SR. (1999). Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer. Cancer Res 59: 2370-2375.
24. Suzuki H, Igarashi S, Nojima M, Maruyama R, Yamamoto E, Kai M et al. (2010). IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcino-genesis 31: 342-349.
25. UK Coordinating Committee on Cancer Research (1988). UKCCCR guide lines for the welfare of animals in experimental neoplasia. Br J Cancer 58: 109-113.
26. Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S et al. (2007). Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA 104: 2803-2808.
27. Wajapeyee N, Kapoor V, Mahalingam M, Green MR. (2009). Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Mol Cancer Ther 8: 3009-3014.
28. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. (2008). Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132: 363-374.
29. Wilson HM, Birnbaum RS, Poot M, Quinn LS, Swisshelm K. (2002). Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ 13: 205-213.
30. Yamanaka Y, Wilson EM, Rosenfeld RG, Oh Y. (1997). Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem 272: 30729-30734. (Pubitemid 27527507)
31. Zeki K, Nakano Y, Inokuchi N, Watanabe K, Morimoto I, Yamashita U et al. (1993). Autocrine stimulation of interleukin-1 in the growth of human thyroid carcinoma cell line NIM 1. J Clin Endocrinol Metab 76: 127-133.